[{"orgOrder":0,"company":"Creapharm","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"Creapharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Creapharm \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Creapharm \/ First Wave BioPharma"},{"orgOrder":0,"company":"Delpharm Group","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"Delpharm Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Delpharm Group \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Delpharm Group \/ First Wave BioPharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Frexalimab","moa":"TNFSF5","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SAR442970","moa":"TAX transcriptionally-activated glycoprotein 1 (OX40)","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"M1 Pram P037","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : SAR442970

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single NanobodyÂ® Molecu...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

February 06, 2025

Lead Product(s) : SAR442970

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Teplizumab

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

January 24, 2025

Lead Product(s) : Teplizumab

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Frexalimab

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on To...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

November 01, 2023

Lead Product(s) : Frexalimab

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Teplizumab

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Sanofi

Deal Size : $35.0 million

Deal Type : Agreement

Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US

Details : The financing will be used to support the commercial launch of TZIELD (teplizumab-mzwv). TZIELD is a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

Product Name : Tzield

Product Type : Antibody

Upfront Cash : Undisclosed

February 13, 2023

Lead Product(s) : Teplizumab

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Sanofi

Deal Size : $35.0 million

Deal Type : Agreement

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

05

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Teplizumab

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Sanofi

Deal Size : $55.0 million

Deal Type : Agreement

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset...

Details : Teplizumab (PRV-031), is an investigational anti-CD3 monoclonal antibody that is being evaluated for the delay of clinical type 1 diabetes (T1D) in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies.

Product Name : Tzield

Product Type : Antibody

Upfront Cash : $20.0 million

June 10, 2022

Lead Product(s) : Teplizumab

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Sanofi

Deal Size : $55.0 million

Deal Type : Agreement

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

06

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Teplizumab

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

February 17, 2020

Lead Product(s) : Teplizumab

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

07

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Sotagliflozin

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderat...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 12, 2018

Lead Product(s) : Sotagliflozin

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

08

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : SAR425899

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 25, 2016

Lead Product(s) : SAR425899

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

09

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Lixisenatide

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Details : Undisclosed

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

October 24, 2014

Lead Product(s) : Lixisenatide

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

10

Sanofi

France

CPhI WW Frankfurt

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Insulin Glargine

Therapeutic Area : Endocrinology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on B...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Peptide

Upfront Cash : Inapplicable

August 07, 2012

Lead Product(s) : Insulin Glargine

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow